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Background: Clinical studies have tested the use of an engineered herpes virus to treat pain. We hypothesized that
subcutaneous injections of an engineered herpes virus that expresses enkephalin would attenuate orofacial
nociception and hypersensitivity in male and female rats by a central mechanism.
Methods: Herpes virus was injected subcutaneously around the mouth of male and female rats seventy-two hours
before ligatures were placed on the masseter tendon, control treatment groups received either no virus or no ligature.
Enkephalin expression was measured and von Frey filament testing and meal duration were utilized to measure
mechanical hypersensitivity and the nociceptive response, respectively. Naloxone or naloxone methiodide was
administered to rats injected with the enkephalin expressing virus to test if enkephalin was acting peripherally or centrally.
Results: Ligature significantly lengthened meal duration and reduced the threshold to von Frey filaments for 18 days.
Infection with the enkephalin transgene significantly decreased this response for at least 11 days but only in male rats.
Virus injection significantly increased expression of enkephalin in the mental nerve that innervates the mouth region, the
trigeminal ganglia and the trigeminal nucleus caudalis but no increase was observed in the masseter nerve after virus
injection. Naloxone but not naloxone methiodide reversed the response to the enkephaline expressing virus.
Conclusions: The data suggests that sex should be a considered when using this virus and that viral transfection of the
mental nerve with an enkephalin transgene can reduce nociception and hypersensitivity through a central mechanism.
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Chronic orofacial pain such as trigeminal neuralgia, atypical
face pain and temporomandibular joint (TMJ) pain are
often refractory to current treatment. Control of trigeminal
neuralgia pain with drugs is effective in some patients [1]
but the effectiveness becomes diminished over time or the
patient has side effects to the drugs [2]. Surgery is another
option but surgery is not effective in 25-30% of trigeminal
neuralgia patients [3,4]. Treatment of TMJ pain by surgical
intervention has limitations and additional treatment op-
tions are necessary [5,6].* Correspondence: pkramer@bcd.tamhsc.edu
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unless otherwise stated.A current pain treatment modality using herpes simplex
type I virus to target neuronal expression of enkephalin is
currently in clinical trials [7]. Examples of this method’s
effectiveness have been demonstrated in an infraorbital
nerve ligature model and a facial inflammatory model [8,9].
Current research is testing viral expression vectors to
enhance enkephalin concentrations and treat pain [10,11].
The basis for treatment with herpes simplex type I virus is
that it attaches to the cell membrane of nerve terminals,
internalizes and then retrogradely transports along axons of
afferent neurons to the cell body where the viral genome is
expressed subsequently affecting cell function [12]. Using
this process genes can be engineered into the viral genome
for transient expression in host neurons [13]. Wilson et al.,
1999 showed that a subcutaneous injection of an engineered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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innervating the injection site. After infection expression of
the transgene occurs within 15 hours [14]. The transfection
of sensory neurons with engineered herpes virus has been
demonstrated for the dorsal root ganglia and trigeminal gan-
glia [8,15]. Herpes virus transfection can be used to cause
the overexpression of enkephalin and GABA in the dorsal
root ganglia to reduce persistent nociception [15-17].
It is unclear if this viral treatment affects men and women
differently. This is important because females report a
higher amount of orofacial pain than men [18]. For ex-
ample, women report trigeminal neuralgia and atypical
facial pain two to three times more often than men [19]
and seek treatment for temporomandibular joint disorders
(TMD) more often than men; such that they comprise over
three-fourths of the clinical cases. Recently it has been
shown that polymorphisms in the estrogen receptor will
increase the risk of women developing TMD, such that,
woman have a significantly higher risk of moderate or se-
vere pain when polymorphisms are present in this receptor
[20,21]; supporting a biological basis for the effect of sex on
TMD [22]. Evidence suggests the orofacial pain response in
men and women is different because of changes in opioid
signaling [23-25]. The opioid enkephalin is affected by sex
steroids in certain regions of the female rat brain [26,27].
To date, no study has utilized a chronic animal model to
study sex differences in myogenic nociception while altering
proenkephalin expression using a viral vector in male and
female rats.
It is unknown if the enkephalin viral vector, such as used
in this study, has the same efficacy in attenuating orofacial
nociception in males and females nor is it clear the location
of enkephalin overexpression. Since enkephalin overexpres-
sion can result in a reduction of the nociceptive response,
locating the enkephalin overexpressing neurons would give
clues to the pathway responsible for attenuation. In the
present experiments an engineered herpes virus was injected
around the mouth and a ligature was placed around the
masseter tendon to induce a persistent myogenic response
(i.e., TMJ myogenic pain model) in both male and female
rats. Mechanical hypersensitivity and the nociceptive re-
sponse were measured using a von Frey filament assay [28]
and a meal duration assay [29,30]. Opioid antagonists nalox-
one and naloxone methiodide were administered to test
enkephalin action peripherally and centrally because nalox-
one methiodide is impermeable to blood brain barrier. The
expression of enkephalin was measured in the mental nerve
(the site of injection), the masseter nerve (the site of ligature)
and regions where these nerves project; the trigeminal
ganglia and the trigeminal nucleus caudalis [31,32].
Methods
The studies were divided into four experiments; Experiment
#1 determined the effect of ligature on meal duration inboth males and female rats. Experiment #2 tested the effect
of enkephalin on the orofacial nociceptive response in male
and female rats by injecting enkephalin producing virus in
the mouth region. Experiment #2 also measured enkephalin
expression in the trigeminal ganglia 18 days after ligature,
the final time point in which von Frey mechanical sensitiv-
ity testing was performed, see Table 1. Experiment #3 mea-
sured enkephalin expression in both peripheral and central
locations when the nociceptive (meal duration) response
was attenuated by virus (4 days post injection). More specif-
ically, male rats were injected with virus, ligatured and the
mental, masseter nerves, trigeminal ganglia and trigeminal
nucleus caudalis were isolated (Table 1). Experiment #4
tested whether enkephalin was acting in the peripheral or
central nervous system to attenuate the behavioral pain
response. To perform this test opioid receptor antagonists
naloxone or naloxone methiodide were administered by
osmotic pumps. Naloxone methiodide does not easily cross
the blood brain barrier and tests antagonistic effects specific
to the peripheral nervous system.
Animal husbandry
The Texas A&M University Baylor College of Dentistry
Institutional Animal Care and Use Committee approved
the experimental protocol. Male (300 gram) and female
(280 gram) Sprague–Dawley rats from Harlan Industries,
Houston, TX were kept on a 14:10 light/dark cycle with
lights on at 06:00 hours. They were acclimated to the
feeding modules for four days before surgery. The rats
were given chow pellets and water ad libitum.
Osmotic pump surgery and drug administration
For surgery rats were anesthetized with 60% of the nor-
mal surgical dose of ketamine (52 mg/kg) and xylazine
(5.4 mg/kg). Using sterile technique anesthetized rats
were implanted with 14-day Alzet mini-osmotic pump
that dispensed 12 μl/day of 0.9% saline (vehicle) or 3 mg
per kg per day of naloxone or naloxone methiodide [8].
Virus construction and transfection
Replication incompetent herpes simplex I virus was engi-
neered to contain either a LacZ control construct (SHZ) or
a construct (SHPE) that expressed human 5 met and 1 leu-
enkephalin under the control of the human cytomegalo-
virus immediate–early promoter inserted in the HSV thy-
midine kinase locus. The viral vectors were generated as
previously described [17] at a concentration of 3.2 × 109
and 4.0 × 109 pfu/ml, respectively. No viral injection was
performed in Experiment #1 but subcutaneous injections
were completed in Experiment #2, #3 and #4 (see Table 1).
Virus expressing SHPE or the SHZ were injected into the
rats using a Hamilton syringe after the rats were anesthe-
tized with isoflurane gas 5% / 95% O2. Vehicle (i.e., PBS)
was injected as a control. Three microliters were injected at
Table 1 Time line for experiments
Day Treatment
Experiment #1
−13 ▪ Male Sprague–Dawley rats from Harlan Industries arrive
−8 ▪ Rats placed in the feeder chambers
−1 ▪ A ligature is placed around the tendon of the masseter muscle, the sham group has the tendon exposed but no ligature is placed
11 ▪ Rats are sacrificed
Experiment #2
−16 ▪ Male Sprague–Dawley rats from Harlan Industries arrive
−13 ▪ Gentled for filament testing
−8 ▪ Rats placed in the feeder chambers
−7 ▪ von Frey filament testing is performed
−4 ▪ Innoculate regions around the mouth with five 3 μl injections of vehicle, SHZ virus (control virus), or SHPE virus
(enkephalin expressing virus)
−1 ▪ von Frey filament testing is performed before surgery
▪ A ligature is placed around tendon of the masseter muscle for those rats in the chronic pain group, the sham group has the
tendon exposed but no ligature is placed
4 ▪ von Frey filament testing is performed
▪ Rats removed from feeders after the enkephalin transgene effect on meal duration was no longer significant
11 ▪ von Frey filament testing is performed
18 ▪ von Frey filament testing is performed
▪ Rats are sacrificed and the trigeminal ganglia is isolated for ELISA
Experiment #3
−13 ▪ Male Sprague–Dawley rats from Harlan Industries arrive
−4 ▪ Innoculate regions around the mouth with five 3 μl injections of vehicle, SHZ virus, or SHPE virus
−1 ▪ A ligature is placed around the tendon of the masseter muscle
1 ▪ Rats are sacrificed and tissue is isolated for RIA
Experiment #4
−13 ▪ Male Sprague–Dawley rats from Harlan Industries arrive
−10 ▪ Gentled for filament testing
−8 ▪ Rats placed in the feeder chambers
−4 ▪ Osmotic pumps surgically implanted subcutaneously contained either vehicle, naloxone or naloxone methiodide
−1 ▪ Gentled for filament testing
▪ Innoculate regions around the mouth with five 3 μl injections of SHPE virus
3 ▪ A ligature is placed around the tendon of the masseter muscle
7 ▪ von Frey filament testing is performed
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(bilaterally) and into the chin (Figure 1). These regions are
innervated by the mental nerve which sends axons directly
to the V3 of the trigeminal ganglia [33].
Ligature placement
Seventy two hours after virus injection (no virus in
experiment #1) a ligature was placed around the tendon
of the anterior superficial portion of the masseter muscle
(TASM); Experiments #1, #2, #3 and #4. TASM results
in inflammatory mediator release from the surrounding
tissues that enhance the activity of adjacent neurons[28,34]. This model has a myogenic component similar
to tenomyositis and muscle pain observed in a human
TMD patient [35-37]. Like a human TMD patient where
inflammation of the masseter muscle occurs at its
attachment to the zygomatic arch (i.e., tenomyositis or
tendomyositis) [38,39]. This model has been show to
induce a nociceptive response for at least 8 weeks [28],
as measured by the rat’s response to press of the skin
over the ligatured tendon with von Frey filaments.
In Experiment #1 ligature(s) were given either unilaterally
or bilaterally to determine if a nociceptive dose response
could be measured. Thus, in a subset of males two 4.0
Figure 1 Cartoon showing at each site, the five locations where
vehicle or virus was injected into each rat.
Table 2 Treatment Groups and animal numbers
Masseter surgery Injection/pump solution Sex # of rats
Experiment #1
Sham surgery No injection male 12
Unilateral ligature No injection male 10
Bilateral ligature No injection male 12
Sham surgery No injection female 12
Bilateral ligature No injection female 12
Experiment #2
Sham surgery vehicle male 8
Bilateral ligature vehicle male 8
Sham surgery control virus (SHZ) male 6
Bilateral ligature control virus (SHZ) male 6
Sham surgery enkephalin virus (SHPE) male 6
Bilateral ligature enkephalin virus (SHPE) male 6
Sham surgery vehicle female 8
Bilateral ligature vehicle female 8
Sham surgery control virus (SHZ) female 6
Bilateral ligature control virus (SHZ) female 6
Sham surgery enkephalin virus (SHPE) female 6
Bilateral ligature enkephalin virus (SHPE) female 6
Experiment #3
Bilateral ligature control virus (SHZ) male 8
Bilateral ligature enkephalin virus (SHPE) male 8
Experiment #4
Bilateral ligature enkephalin virus (SHPE)/
vehicle pump
male 6
Bilateral ligature enkephalin virus (SHPE)/
naloxone pump
male 6
Bilateral ligature enkephalin virus (SHPE)/
naloxone methiodide pump
male 6
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038727), spaced approximately 3.0 mm apart were placed
randomly on the masseter tendon on a single side of the
head (Table 1). In a different group of male rats a bilateral
ligature of the TASM was completed by placing two 4.0
chromic gut ligatures, spaced approximately 3.0 mm apart
around the tendon on both sides of the head [28]. Female
rats were given bilateral ligatures in Experiment #1. In Ex-
periment #2, #3 and #4 only bilateral ligatures were placed.
The incision in the mouth was closed with a single 5.0
polyglycolic acid suture using a 13 mm 3/8 needle (Butler
Schein Cat# 493A). Sham operated rats received the same
surgery but the tendon was not ligated.
Meal duration assay
Meal duration can be used as a non-invasive biological
marker for TMJ nociception for up to 19 days [29]. Male
and female rats with TMJ arthritis eat more slowly,
which significantly lengthens the meal duration and
pharmacological intervention that reduces pain and in-
flammation returns the meal duration to normal [40-42].
Patients experiencing TMD pain also have longer chew-
ing cycles and cycle length [43-45]. The lengthening of
meal duration during TMD pain [35] is a “guarding
behavior”, which can be argued as an operationally
defined nociceptive behavior [46].
For the meal duration assay the rats were housed
individually in sound-attenuated chambers equipped
with photobeam computer-activated pellet feeders (Med
Assoc. Inc., East Fairfield, VT) loaded with 45 mg rodent
chow pellets (Product No. FO 165, Bioserv, Frenchtown,
NJ). When a rat removed a pellet from the feeder
trough, a photobeam placed at the bottom of the trough
was no longer blocked, signaling the computer to drop
another pellet. The computer recorded the date and
time and kept a running tally of the total daily food con-
sumption. In these analyses, a meal was defined using a10-min end of meal criterion (i.e., a meal was bracketed
before and after by a 10 minute period of no pellets
being taken) and the minimum meal size was set at two
pellets [47]. In Experiment #1 (see Table 1) rats were
placed in the feeders one week before the ligature
surgery and the rats remained in the feeders for 10 days
after ligature. In Experiment #2 and #4 the rats were
placed in the feeders one week before ligature surgery
but remained in the feeder for 4 days after ligature. The
daily meal duration was then calculated using Med
Assoc. Inc. and proprietary software. The number of
animals in each group is shown in Table 2.
Filament testing
von Frey filament testing was completed in Experi-
ment #2 and #4. In these tests the animals were
gentled by handling a week before filament testing. The
filament tests were performed using a series of calibrated
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tendon (see Table 1 for testing timeline). An active with-
drawal of the head from the probing filament was defined
as a response. Each von Frey filament was applied five times
at intervals of a few sec. The response frequencies (EF50)
were calculated as described by Ren’s group [28]. Briefly,
the response frequencies [(number of responses/number of
stimuli) × 100%] to a range of von Frey filament forces were
determined and a stimulus–response frequency curve was
plotted. After a non-linear regression analysis, the half
maximal response [i.e., EC50 values calculated by Prism 5.0
software (GraphPad, Inc.), here termed EF50] value was
derived from the stimulus response curve.
Tissue isolation, ELISA and RIA assay
No tissue was isolated in Experiment #1. In Experiment
#2 the trigeminal ganglia was isolated 18 days after liga-
ture. In Experiment #3 the mental and masseter nerves
were isolated along with the trigeminal ganglia and tri-
geminal nucleus caudalis four days after virus infection
(Table 1). Note: the mental nerve is adjacent to the site
of injection. The masseter nerve innervates the ligature
site and the masseter and mental nerves project to the
trigeminal ganglia and then to the caudalis [31,32].
The trigeminal ganglia from each rat just rostral of V1
and 2 mm caudal of V3 was dissected after removal of
the brain. To isolate the caudalis nuclei a slice of brain-
stem was collected from a tissue block that included a
2-mm segment beginning 4–5 mm caudal to the obex.
This tissue block included the caudal laminated (Vc) and
upper cervical spinal cord (C1). The tissue block was
turned coronally and the superficial portion of the Vc
was harvested. For masseter nerve isolation the tempor-
alis, the masseter and the zygomatic arch were exposed.
The temporalis and the masseter were cut immediately
above and below the zygomatic arch respectively. The
temporalis muscle was reflected and the arch was
broken as close to the bodies of the zygomatic and tem-
poral bones as possible and removed. This exposed the
superior aspect of the infratemporal fossa. Next, the cor-
onoid process of the mandible was broken off with ron-
geurs and removed. The masseter nerve was within or
immediately anterior to the connective tissue capsule of the
TMJ since the masseter nerve projects to V3 of the trigemi-
nal ganglia. A vertical incision in the masseter muscle was
made to expose more of the nerve branching within the
mass of the muscle. The nerve was traced back toward the
foramen ovale along the inferior aspect of the temporal
bone. The nerve was extracted by cutting the exposed nerve
near foramen ovale proximally and within the tissue of the
masseter muscle distally. To isolate the mental nerve
the skin to the base of the incisors on the inferior aspect of
the head, the connective tissue overlying the incisive alveo-
lar processes was cut to the bone in the anteroposteriordirection and reflected anteriorly and laterally. The reflec-
tion of the connective tissue exposed the mental foramen
on the lateral side of the base of the incisive alveolar process
with the mental nerve emerging from the foramen. The
nerve was exposed by gently teasing apart the connective
tissues at the distal end of the nerve. The nerve was ex-
tracted by cutting it at the mental foramen proximally and
as close to the connective tissue of the skin distally. Each
tissue was stored separately in liquid nitrogen until analysis.
Tissue was placed in 300 μl of T-Per tissue protein extrac-
tion reagent containing Halt Protease Inhibitor and ground
(Thermo Scientific, Rockford, IL, Cat#78510). Human
enkephalin quantitation was completed on duplicate 100 μl
samples of supernatant in Experiment 2 using an ELISA
following the manufacturer’s directions (MyBioSource, San
Diego, CA, Cat# MBS269873). Human and rat met-
enkephalin quantitation was completed on duplicate 100 μl
samples of supernatant in Experiment #3 using an RIA fol-
lowing the manufacturer’s directions (Peninsula Laborator-
ies International Inc., San Carlos, CA, Cat# S-2119). In
Experiment #2 and Experiment #3 total protein in the
supernatant samples of the trigeminal ganglia and trigemi-
nal nucleus caudalis samples was determined using a BCA
protein assay (Thermo Scientific, Waltham, WA, Cat# PI-
23221). Isolation of the masseter and mental nerve included
a variable amount of connective and muscle tissue, thus to
standardize the amount of nervous tissue in each sample
we quantitated the amount of 68 kDa light neurofilament
(NEFL) in each sample by ELISA following the manufac-
tures directions (Novus Biologicals, Littleton CO, Cat#
KA1478). Values were given either as the ng of met-
enkephalin per mg of total protein or for the masseter and
mental nerve ng of met-enkephalin per ng of NEFL.
Statistics
Filament data was analyzed using a Mann Whitney test.
Meal duration and enkephalin concentration and body
weights were analyzed by ANOVA with the dependent
variables being meal duration or enkephalin concentra-
tion or body weight and the independent variables being
surgery, substance injected, sex or days (Prizm 5.0,
GraphPad Software Inc, La Jolla, CA). Groups with sig-
nificant main effects were further analyzed by Duncan’s
post-hoc test. In Experiment #3 and Experiment #4 the
data was analyzed with a t-test.
Results
Experiment #1: Ligature model tested in male and
females rats
Ligation resulted in a significant increase in meal duration
for both the male F(2, 386) = 21.42, p < 0.01 (Figure 2A, six
day increase) and female rats F(1, 352) = 39.65, p < 0.01
(Figure 2B, eight day increase) with a significant interaction
between days and surgery for both the males F(22, 386) =
Figure 2 Experiment #1: Meal duration in male and female rats
after masseter tendon ligation. Sham rats were given anesthetic
and the tendon was exposed but no ligature was placed and
ligature rats had a tight ligature tied around the tendon of the
masseter muscle. In panel A the ligature was randomly placed on
one side or both sides of a male rat’s masseter tendon to determine
a dose response to the surgical treatment and then meal duration
was measured. A non-ligatured control group was also included (i.e.,
sham). In panel B, meal duration was measured for female rats with
bilateral ligatures. Meal duration values are given for four days before
ligature (−4, −3, −2, −1) and for 10 days after ligature (1, 2, 3, 4, etc.).
Body weight (panel C) was measured daily for the male and female
rats. Values are the means ± SEM. Significant differences between
the ligature groups and their respective sham groups are indicated
by * = p < 0.05. See Table 2 for the number of animals per group.
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p < 0.01 (Figure 2B). No significant difference in meal dur-
ation was observed between the males and females. To test
the dose response of placing a ligature, male rats had either
both tendons ligatured or a single tendon ligatured. Ratsthat had both tendons ligatured had a significantly longer
meal duration versus rats that had a ligature placed on only
a single side F(1, 231 = 5.43), p < 0.05 with no interaction
between days and surgery F(11, 231) = 0.64, p > 0.79
(Figure 2A).
Meal number, meal size, food intake and body weight
were not reliable indicators for nociception after TASM
ligature (data not shown) consistent with results from
rats with TMJ inflammation [29] and from rats with an
exposed pulp [29,48].
Body weight values were statistically analyzed and the
results show that ligature did not significantly alter body-
weight in either the male or female groups [Figure 2C;
F(1,89) = 1.16, p = 0.28]. As expected, the female rats did
have a significantly lower body weight gain in comparison
to the male rats [Figure 2C; F(1,89) = 32.3, p < 0.001].
Experiment #2: Enkephalin transgene expression
increased and reduced the nociceptive response in male
and female rats
The amount of human enkephalin in the trigeminal ganglia
was significantly higher in the male F(1,19) = 9.0, p < 0.01
(Figure 3A) and female F = (1,26) = 47.7, p < 0.001
(Figure 3B) rats three weeks after injecting the SHPE con-
struct versus rats injected with the vehicle and SHZ control
virus. Enkephalin expression in the male trigeminal ganglia
was not significantly different than enkephalin expression in
the females. No significant interaction was observed between
virus injection and ligature surgery for either the males
F(1,19) = 0.25, p < 0.61 or females F(1, 26) = 0.03, p < 0.85.
In male rats the meal duration was significantly longer in
the vehicle/ligature and SHZ/ligature groups versus their
respective sham groups (Figure 4A). The main effect for
surgery was F(1,237) = 8.5, p < 0.01 but there was no inter-
action between surgery and virus injection F(2, 237) = 1.0,
p = 0.37. Filament testing revealed a greater injury induced
mechanical hypersensitivity in the ligated groups versus the
respective sham groups for 18 days post-ligature (Figure 4B).
Meal duration was significantly reduced F(2, 204) = 4.8,
Figure 3 Experiment #2: Human met-enkephalin in the rat
trigeminal ganglia after injection of herpes virus expressing the
enkephalin transgene or a control virus. A single randomly
chosen trigeminal ganglia was removed three weeks after injection
(see Experiment 2, Table 1) and the human enkephalin protein was
quantitated by ELISA. Measurements were made in both male
(panel A) and female (panel B) rats. Groups received either a
vehicle injection or an injection of virus that did not contain an
enkephalin transgene (control virus, SHZ) or a virus that had an
enkephalin transgene (SHPE). The vehicle and SHZ control groups
were not significantly different than the zero ng met-enkephalin
standard provided in the ELISA kit and the values obtained for these
groups were considered background and combined in Figure 3A
and 3B. Values are the means ± SEM. An asterisk indicates a
significant difference (p < 0.05) between the vehicle & SHZ control
groups versus the SHPE virus group. See Table 2 for the number of
animals per group.
Figure 4 Experiment #2: Meal duration and von Frey filament
testing of male rats after virus injection. Rats were injected with
virus and then 72 hours post-injection a ligature was placed around
the tendon of the masseter muscle. Meal duration (panel A) was
reported for 6 days before ligature surgery (−6, −5, −4, −3, −2, −1)
and for 4 days after ligature surgery (1, 2, 3, 3). Filament testing was
reported for day 7 before ligature surgery (-7) and 7, 14 and 21 days
post-virus injection or 4, 11 and 18 days post-ligature (panel B).
Groups received either a vehicle injection or an injection of virus
that did not contain an enkephalin transgene (control virus, SHZ) or
a virus that had an enkephalin transgene (SHPE) on day −4. In panel
A the significant differences (p < 0.05) between the vehicle/ligature,
SHZ virus/ligature and their respective sham groups are indicated
by an asterisk and significant differences (p < 0.05) between the
vehicle/ligature and SHZ/ligature versus the SHPE virus/ligature group
are indicated by a “#”. In panel B significant differences (p < 0.05)
between all the ligature groups and their respective sham groups
are indicated by an asterisk and significant differences (p < 0.05)
between the vehicle/ligature and SHZ/ligature versus the SHPE
virus/ligature group is indicated by a “#”. Values are the means ±
SEM. See Table 2 for the number of animals per group.
Kramer et al. BMC Neurology  (2015) 15:34 Page 7 of 12p < 0.01 in the SHPE virus injected/ligatured rats versus the
ligatured rats that received either vehicle or the control
SHZ virus (Figure 4A). Upon filament testing a significantly
reduced mechanical hypersensitivity was observed in the
SHPE virus injected/ligatured rats for 11 days post-injection
(Figure 4B).
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meal duration F(2, 319) = 9.3, p < 0.01 (Figure 5A) but in
striking contrast with the male data, treatment with the
SHPE virus had no significant effect on the meal duration FFigure 5 Experiment #2: Meal duration and von Frey filament
testing of female rats after virus injection. Rats were injected
with virus and then 72 hours post-injection a ligature was placed
around the tendon of the masseter muscle. Meal duration (panel A)
was reported for 6 days before ligature surgery (−6, −5, −4, −3, −2,
−1) and for 4 days after ligature surgery (1, 2, 3, 3). Filament testing
was reported for day 7 before ligature surgery (-7) and 7, 14 and
21 days post-virus injection or 4, 11 and 18 days post-ligature (panel B).
Groups received either a vehicle injection or an injection of virus
that did not contain an enkephalin transgene (control virus, SHZ)
or a virus that had an enkephalin transgene (SHPE) on day −4.
Significant differences of (p < 0.05) between the ligature groups and
their respective sham groups are indicated by an asterisk and
significant differences (p < 0.05) between the vehicle/ligature and
SHZ/ligature group is indicated by a “#”. Values are the means ±
SEM. See Table 2 for the number of animals per group.(2, 164) = 1.14, p = 0.3. Filament testing indicated there was
a significantly greater mechanical hypersensitivity for the
18 day measurement period in female rats after ligature sur-
gery (Figure 5B) which was similar to the males. However,
in contrast to the male data, injection with the SHPE
virus had no significant effect on attenuating mechanical
hypersensitivity (see Additional file 1: Figure S1). Note that
injection of virus or surgery did significantly affect the
mechanical hypersensitivity (compare the vehicle/ligature
and SHZ/ligature groups in Figure 5B).
Experiment #3: met-enkephalin expression increased in
the mental nerve, trigeminal ganglia and trigeminal
nucleus caudalis after injection of virus
Expression of enkephalin increased significantly in the men-
tal nerve (Figure 6A) but not the masseter nerve (Figure 6B)
after injection of SHPE virus. Injection of the enkephalin
expressing virus (i.e., SHPE) induced a significant increase
in met-enkephalin in both the trigeminal ganglia (Figure 6C)
and trigeminal nucleus caudalis (Figure 6D).
Experiment #4: Opioid antagonists reduced enkephalins
attenuation of the allodynic and nociceptive response
Administration of naloxone but not naloxone methio-
dide lenghthened the meal duration (Figure 7A) and
reduced the allodynic threshold (Figure 7B) of ligatures
rats injected with enkephalin expressing virus.
Discussion
The data for Experiment #1 demonstrate that ligation of
the TASM can increase nociception and hypersensitivity as
measured by two different techniques i.e., meal duration
and filament testing thus, confirming the TASM model of
Guo et al., [28]. In this study we demonstrate for the first
time that the nociceptive response increases as you ligature
a greater number of masseter tendons (i.e., bilateral versus
unilateral). The data also showed that ligatured females had
a significantly longer nociceptive response (i.e., meal dur-
ation was lengthened for 8 days) compared to males
(6 days), and also extend the ligature model by demonstrat-
ing that it is valid for female rats as well as male animals.
These data fit well with previous animal studies showing
that male rats have a reduced response to muscle stimula-
tion [49] and TMJ inflammation [41,50,51]. Using this
model the effect of an enkephalin transgene was different
for male and female rats. Enkephalin expression in the tri-
geminal ganglia of the male rats reduced the nociceptive
response after TASM ligature but had no effect in the
female rats.
Enkephalin expression in Experiment #2 reduced the re-
sponse in males but not females when assayed by both meal
duration and von Frey testing suggesting enkephalin modu-
lation of the pain response may be different in male and
female rats. Measurement of enkephalin expression in the
Figure 6 Experiment #3: Human and rat met-enkephalin in various tissues after injection of herpes virus expressing the enkephalin
transgene. Various neuronal tissues were removed from male rats four days after injection (see Experiment #3, Table 1) and the total amount of
enkephalin protein was quantitated by RIA. Measurements were made in the A) mental nerve, B) masseter nerve, C) trigeminal ganglia and D)
the trigeminal nucleus caudalis. Values are the means ± SEM. An asterisk indicates a significant difference (p < 0.05) between the SHZ control
group and the SHPE virus group. See Table 2 for the number of animals per group.
Kramer et al. BMC Neurology  (2015) 15:34 Page 9 of 12trigeminal ganglia in Experiment #2 indicated that the
amount of human enkephalin produced after viral injection
was not significantly different between the male and female
rats after three weeks. This supports previous studies that
indicate herpes virus transport of genetic material is an
effective means of introducing gene expression in neurons
[52]. The finding that enkephalin expression was similar in
the male and female rats is important because enkephalin
expression can be modulated by sex steroids in certain
regions of the female rat brain [26,27], however we did not
observe this sex effect in the trigeminal ganglia. The fact
that there was no significant difference could be explained
by the strong cytomegalovirus immediate–early promoter
driving expression of the enkephalin gene in the viral con-
struct. Enkephalin expression was measured 21 days post-
virus injection but future studies would need to address the
possibility that enkephalin expression was greater in the
males prior to this sampling time (i.e., within the first two
weeks after virus injection).
If enkephalin concentration was the same in males and
females, consistent with our existing data, then why do
females show no significant attenuation of nociception
following virus treatment? One possibility is that the delta-
opioid system is inherently less active in females as demon-
strated by the need for a greater amount delta-opioidreceptor agonist to treat orofacial hyperalgesia in female
rats [24]. A second possibility is that females have different
mu-opioid activity. For example, the trigeminal ganglia con-
tains mu-opioid receptors [53] that when activated reduce
nociception in rats with masseter muscle inflammation
[54]. Neurons from the trigeminal ganglia project axons
that terminate in the trigeminal nucleus caudalis where
estrogen can binds its receptor to alter the opioid pathway
[55]. This mu-opioid system is attenuated in cycling females
when the estrogen levels are at a nadir (i.e., diestrus) [23]
but when estrogen levels peak the mu-opioid system has
greater activity, equivalent to men [56]. This decrease or in-
crease in the mu-opioid system’s activity can be associated
with a respective increase or decrease of the nociceptive re-
sponse [57,58]. Because enkephalin has a high binding affin-
ity for mu and delta opioid receptors one explanation for
our results is that the females had reduced mu or delta-
opioid activity in comparison to the males. We suggest this
possibility based on studies that show estrogen attenuates
antinociception through an opioid pathway [59], possibly
mediated by opioid neurons that co-express the estrogen
receptor [55,60].
Injections of met-enkephalin producing SHPE virus
reduced the nociceptive response but we wanted to de-
termine if the effects were peripheral or central. Orofacial
Figure 7 Experiment #4. Meal duration and von Frey filament
testing of ligatured male rats given opioid antagonist and a viral
enkephalin expression vector. Osmotic pumps releasing vehicle,
naloxone or naloxone methiodide were surgically implanted
subcutaneously in rats. Rats were injected with SPHE virus 72 hours
after pump implantation. A ligature was placed around the tendon
of the masseter muscle 72 hours after SPHE virus injection. Meal
duration (panel A) was reported for the day after and von Frey
filament testing (panel B) was reported on the 4th day after ligature
surgery (see Table 1). Significant differences (p < 0.05) between the
groups are indicated by an asterisk. Values are the means ± SEM. See
Table 2 for the number of animals per group.
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pathway peripherally [25,61]. Experiment #3 was performed
for the purpose of determining met-enkephalin expression
four days after virus injection; the time when meal durationwas significantly attenuated. The experiment was limited to
male rats that received ligature to reduce animal numbers.
No significant increase in enkephalin was observed in the
masseter nerve suggesting the spread of virus was localized
to the injection site and peripheral effects were localized to
sensory nerves innervating the injected region. Central
action of enkephalin was supported by an observed increase
in enkephalin in the trigeminal nucleus caudalis. Experi-
ment #4 confirmed this result in that naloxone methiodide,
which has difficulty crossing the blood brain barrier, did not
reverse the effects of the enkephalin virus whereas naloxone
did. A possible mechanism for this effect is by enkephalin
binding delta opioid receptors in the caudalis, activating
GIRK channels effecting other central sites that cause a
attenuation of the masseteric hyperalgesia [62].
Measurement of the enkephalin protein in Experiment
#2 was completed by an ELISA assay that had specificity
for human enkephalin, note that the SHPE virus
expressed the human enkephalin gene. The ELISA may
cross react with rat met-enkephalin to a limited degree
because we did observe some signal in the SHZ control
group. The ELISA had a small amount of background
signal as observed in the standard that had zero ng of
human met-enkephalin.
Samples in Experiment #2 were near the minimum sensi-
tivity of the ELISA assay thus, in Experiment #3 we choose
to utilize a more sensitive RIA assay. The RIA assay de-
tected both human and rat met-enkephalin unlike the
ELISA which was reported to be specific for human met-
enkephalin. In Experiment #2 the met-enkephalin in the tri-
geminal ganglia of SHPE injected, ligatured rats increased
0.32 ng ± 0.15 versus controls and in Experiment #3 the
met-enkephalin increased 0.8 ng ± 0.4 when comparing the
same groups suggesting that, within the error of the assay,
the increase in enkephalin after infusion of the SHPE virus
was similar as measured by both ELISA and RIA.
A large proportion of TMD in humans involves orofa-
cial muscles [23,63], which appear to be important in
producing long lasting and severe orofacial pain. In this
regard, the TASM ligature model was an improvement
from previous models because it produces pain for days
versus models that use formalin or hypertonic saline in-
jections. Thus, the benefits of the TASM model are at
least two fold, first the model utilized orofacial muscles
which contribute to the pain reported in a majority of
TMD patients. Second, the model produced a long
lasting nociceptive response versus masseter injection of
saline or formalin. TASM ligation results in neuronal
activity due, in part, to nociceptive neurons near the
tendon (e.g., fascia, muscle and connective tissue) [64]
becoming sensitized as the result of biochemical changes
in and around the tendon [65,66]. One example of these
biochemical changes is an increased MMP-9 [67] result-
ing in greater sensitivity of the nociceptive neurons in
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masseter tendon has been shown to increase NMDA
receptor expression within the Vc-C1 region [28] which
corresponded to greater c-fos expression in the trigemi-
nal nucleus and a significantly greater nociceptive response
18 days post treatment.
Body weight was not affected by TASM ligature in either
the females or males and the differences were noted solely
as the result of sex differences in growth rates. A potential
confounder in the feeding model is that ligature of the ten-
don could stimulate neurons of the Golgi organs to reduce
function of the masseter muscle. The fact that the rat’s meal
patterns (i.e., food intake, meal frequency and meal size)
remained unchanged suggests that that ligation did not
inhibit the mechanical feeding processes.
Conclusions
Sex should be a consideration when utilizing virally me-
diated enkephalin expression to treat pain. Enkephalin
overexpression observed in the trigeminal nucleus cau-
dalis and trigeminal ganglia but not the masseter nerve
suggests attenuation of hypersensitivity and the nocicep-
tive response was mediated more centrally.
Additional file
Additional file 1: Figure S1. Experiment #2: Meal duration for male
and female rats one day after ligature surgery. Rats were injected with
virus and then 72 hours post-injection a ligature was placed around the
tendon of the masseter muscle. Meal duration is reported for the day
after surgery. Groups received either a vehicle injection or an
injection of virus that did not contain an enkephalin transgene (control
virus, SHZ) or a virus that had an enkephalin transgene (SHPE) 72 hours
before ligature surgery. A significant difference (p<0.05, t-test) between
the male and females was observed in rats that received the SHPE virus
(asterisk). See Table 2 for the number of animals per group.
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